ANIX Stock Price, Anixa Biosciences Inc Quote, Chart

Market Summary

USD3.24+0.26

Market Closed

8.72%

ANIX Alerts

1 major insider buys recently.

ANIX Stock Price

View Fullscreen

ANIX RSI Chart

ANIX Valuation

Market Cap

103.4M

Price/Earnings (Trailing)

-9.62

Price/Sales (Trailing)

492.17

EV/EBITDA

-10.94

Price/Free Cashflow

-15.83

ANIX Price/Sales (Trailing)

ANIX Profitability

EBT Margin

-4548.42%

Return on Equity

-43.67%

Return on Assets

-42.35%

Free Cashflow Yield

-6.32%

ANIX Fundamentals

ANIX Revenue

Revenue (TTM)

210.0K

Rev. Growth (Qtr)

-100%

ANIX Earnings

Earnings (TTM)

-10.7M

Earnings Growth (Yr)

-40.18%

Earnings Growth (Qtr)

-21%

Breaking Down ANIX Revenue

Last 7 days

3.9%

Last 30 days

0.3%

Last 90 days

-26.0%

Trailing 12 Months

-20.8%

How does ANIX drawdown profile look like?

ANIX Financial Health

Current Ratio

15.19

Debt/Equity

0.07

Debt/Cashflow

-3.72

ANIX Investor Care

Shares Dilution (1Y)

3.16%

Diluted EPS (TTM)

0.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	436.5K	361.0K	285.5K	210.0K
2021	763.0K	513.0K	513.0K	512.0K
2019	0	1.4M	612.5K	250.0K
2018	0	918.8K	1.5M	1.1M
2017	0	0	331.3K	362.5K
2016	0	0	4.8M	300.0K
2015	0	0	0	9.3M
2014	0	0	0	0
2013	0	0	0	388.9K
2012	1.4M	1.6M	1.4M	940.0K
2011	798.8K	866.9K	935.1K	1.0M
2010	0	0	0	730.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Anixa Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	titterton lewis h jr	bought	49,229	3.28	15,009	-
Mar 15, 2024	baskies arnold m	bought	36,300	3.63	10,000	-
Mar 15, 2024	kumar amit	bought	96,600	3.22	30,000	chief executive officer
Oct 31, 2023	catelani michael	acquired	3,004	2.69	1,117	president, coo & cfo
Oct 10, 2023	titterton lewis h jr	acquired	41,200	2.575	16,000	-
Jul 31, 2023	kumar amit	sold	-42,126	3.57	-11,800	chief executive officer
Jul 28, 2023	kumar amit	acquired	103,000	2.575	40,000	chief executive officer
Jul 28, 2023	kumar amit	sold (taxes)	-103,001	3.63	-28,375	chief executive officer
Jul 27, 2023	titterton lewis h jr	acquired	309,000	2.575	120,000	-
Jul 27, 2023	titterton lewis h jr	sold (taxes)	-308,999	3.55	-87,042	-

Which funds bought or sold ANIX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-9.94	-103,422	271,597	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	2,989	27,000	28,000	-%
Apr 24, 2024	Gemmer Asset Management LLC	unchanged	-	-26,600	109,200	0.01%
Apr 24, 2024	Dakota Wealth Management	unchanged	-	-11,400	46,800	-%
Apr 24, 2024	Simplicity Wealth,LLC	new	-	43,583	43,583	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	2.5	-27,000	128,000	-%
Apr 23, 2024	NATIONS FINANCIAL GROUP INC, /IA/ /ADV	unchanged	-	-11,400	46,800	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-68.09	-160,522	55,396	-%
Apr 19, 2024	Westside Investment Management, Inc.	unchanged	-	-10,564	43,368	0.01%
Apr 17, 2024	BARRETT & COMPANY, INC.	unchanged	-	-60.00	250	-%

Are Funds Buying or Selling ANIX?

Are funds buying ANIX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANIX

No. of Funds

ANIX Alerts

1 major insider buys recently.

Unveiling Anixa Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 16, 2024	kumar amit	13.5%	4,884,702	SC 13D/A
Sep 03, 2021	kumar amit	10.3%	3,423,112	SC 13D/A
Jun 10, 2021	kumar amit	8.6%	2,795,889	SC 13D/A
Feb 05, 2021	titterton lewis h jr	5.4%	1,445,326	SC 13D/A

Recent SEC filings of Anixa Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	4	Insider Trading
Mar 22, 2024	8-K	Current Report
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 12, 2024	10-Q	Quarterly Report
Feb 08, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Anixa Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Anixa Biosciences Inc News

Latest updates

Anixa Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2021Q4	2021Q3	2021Q2	2021Q1	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3	2018Q2	2017Q4	2017Q3	2016Q4	2016Q3	2015Q4	2015Q3
Revenue	-	-	-	-	210,000	140,000	70,000	-	-	513,000	-	-	250,000	-	362,500	750,000	-	362,500	326,667	290,833	255,000	140,000
Costs and Expenses	18.3%	3,609,000	3,051,000	2,844,000	2,770,000	2,556,000	4,076,500	4,388,000	2,437,000	2,746,000	2,128,631	2,184,412	2,843,234	5,407,714	5,968,304	2,150,954	-	-	-	-	-	-
S&GA Expenses	57.4%	2,260,000	1,436,000	1,756,000	1,611,000	1,488,000	1,903,500	2,221,000	1,415,000	1,533,000	1,257,443	1,056,963	1,281,966	2,309,275	2,703,752	908,767	-	-	-	-	-	-
R&D Expenses	-16.5%	1,349,000	1,615,000	1,088,000	998,000	1,068,000	2,173,000	2,167,000	1,022,000	828,000	871,188	1,085,574	1,269,393	2,432,906	2,942,071	660,193	-	-	-	-	-	-
EBITDA Margin	0%	-45.19	-45.19	-35.10	-28.69	-24.26	-18.58	-18.54	-18.53	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	325	277	264	1,134	1,946	18,364	-	-	-	-	57,762	71,667	136,708	132,357	118,127	115,981
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-2,111,061	-2,166,048	-2,574,934	-5,391,520	-5,593,576	-1,392,514	-1,785,820	-1,794,400	-1,047,670	-1,103,775	-1,292,413	-1,602,179
EBT Margin	0%	-45.48	-45.48	-35.32	-28.87	-24.42	-18.66	-18.62	-18.62	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-21.0%	-3,255,000	-2,690,000	-2,511,000	-2,288,000	-2,322,000	-4,013,000	-4,334,000	-2,399,000	-2,208,000	-2,026,488	-2,140,028	-2,574,934	-5,391,520	-5,593,576	-1,392,514	-	-	-	-	-	-
Net Income Margin	-9.5%	-51.16	-46.72	-39.19	-32.74	-30.90	-25.30	-21.76	-18.31	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-17.3%	-2,309,000	-1,969,000	-1,445,000	-807,000	-1,988,000	-1,045,000	-1,481,000	-1,242,000	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.6%	25.00	26.00	27.00	28.00	28.00	30.00	33.00	33.00	35.00	36.00	37.00	38.00	15.00	9.00	9.00	6.00	9.00	6.00	7.00	8.00	6.00
Current Assets	-0.5%	25.00	25.00	26.00	27.00	28.00	30.00	32.00	33.00	35.00	36.00	37.00	38.00	15.00	9.00	9.00	6.00	6.00	6.00	7.00	7.00	6.00
Cash Equivalents	9.1%	1.00	1.00	3.00	6.00	10.00	12.00	24.00	28.00	30.00	29.00	27.00	28.00	12.00	6.00	6.00	3.00	3.00	3.00	4.00	4.00	4.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-17.8%	2.00	2.00	2.00	2.00	1.00	2.00	2.00	1.00	2.00	1.00	-	-	-	1.00	1.00	1.00	1.00	1.00	-	-	-
Current Liabilities	-18.1%	2.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	2.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00
Shareholder's Equity	1.1%	25.00	24.00	26.00	26.00	27.00	28.00	31.00	31.00	33.00	35.00	36.00	37.00	13.00	8.00	8.00	5.00	5.00	5.00	5.00	6.00	5.00
Retained Earnings	-1.4%	-231	-228	-225	-222	-220	-218	-214	-212	-208	-204	-200	-196	-194	-191	-189	-187	-184	-181	-179	-177	-175
Additional Paid-In Capital	1.4%	256	252	251	249	248	247	246	244	242	240	237	234	207	200	198	192	190	187	185	184	180
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Shares Outstanding	2.0%	32.00	31.00	31.00	31.00	31.00	31.00	31.00	30.00	30.00	30.00	30.00	31.00	-	-	-	-	-	-	-	-	-
Minority Interest	-3.6%	-1.00	-0.97	-0.93	-0.90	-0.88	-0.85	-0.79	-0.76	-0.72	-0.67	-0.61	-0.56	-0.52	-0.50	-0.48	-0.46	-0.45	-0.42	-0.40	-0.37	-0.34
Float	-	-	-	-	121	-	-	-	93.00	-	-	-	140	-	-	-	35.00	-	-	-	72.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-17.3%	-2,309	-1,969	-1,445	-807	-1,988	-1,593	-1,396	-2,306	-1,197	-1,045	-1,481	-1,242	-1,170	-1,414	-1,290	-1,556	-1,914	-1,337	-640	-1,434	-1,329
Share Based Compensation	-4.2%	1,108	1,157	1,153	1,155	957	1,072	1,330	1,463	2,135	2,699	3,048	881	875	-	-	-1,110	1,021	-9,294	831	-1,321	2,750
Cashflow From Investing	121.8%	129	-593	-980	-3,444	-585	-9,917	-2,911	250	1,850	2,807	1,000	-8,399	675	500	-520	250	-535	-250	650	-1,175	250
Cashflow From Financing	711.1%	2,263	279	3.00	81.00	3.00	-384	829	-	-	144	-	25,361	6,061	1,403	4,851	1,373	1,780	682	565	2,280	2,176

ANIX Income Statement

2024-01-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Revenue
Operating costs and expenses:
Research and development expenses (including non-cash share-based compensation expenses of $489 and $505, respectively)	1,349	1,068
General and administrative expenses (including non-cash share-based compensation expenses of $771 and $558, respectively)	2,260	1,488
Total operating costs and expenses	3,609	2,556
Loss from operations	(3,609)	(2,556)
Interest income	319	202
Net loss	(3,290)	(2,354)
Less: Net loss attributable to noncontrolling interest	(35)	(32)
Net loss attributable to common shareholders	$ (3,255)	$ (2,322)
Net loss per common share attributable to common shareholders:
Basic	$ 0.10	$ 0.08
Diluted	$ 0.10	$ 0.08
Weighted average common shares outstanding:
Basic	31,446	30,921
Diluted	31,446	30,921

ANIX Balance Sheet

2024-01-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jan. 31, 2024	Oct. 31, 2023
Current assets:
Cash and cash equivalents	$ 998	$ 915
Short-term investments	22,800	22,929
Receivables	391	270
Prepaid expenses and other current assets	1,030	1,242
Total current assets	25,219	25,356
Operating lease right-of-use asset	153	166
Total assets	25,372	25,522
Current liabilities:
Accounts payable	364	206
Accrued expenses	1,242	1,770
Operating lease liability	54	52
Total current liabilities	1,660	2,028
Operating lease liability, non-current	108	123
Total liabilities	1,768	2,151
Commitments and contingencies (Note 10)
Equity:
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,754,375 and 31,145,219 shares issued and outstanding as of January 31, 2024 and October 31, 2023, respectively	318	311
Additional paid-in capital	255,738	252,222
Accumulated deficit	(231,451)	(228,196)
Total shareholders’ equity	24,605	24,337
Noncontrolling interest (Note 2)	(1,001)	(966)
Total equity	23,604	23,371
Total liabilities and equity	25,372	25,522
Series A Convertible Preferred Stock [Member]
Equity:
Preferred stock, value

About Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

CEO	Dr. Amit Kumar Ph.D.
WEBSITE	anixa.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Anixa Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Anixa Biosciences Inc? What does ANIX stand for in stocks?

ANIX is the stock ticker symbol of Anixa Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anixa Biosciences Inc (ANIX)?

As of Fri Apr 26 2024, market cap of Anixa Biosciences Inc is 103.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIX stock?

You can check ANIX's fair value in chart for subscribers.

What is the fair value of ANIX stock?

You can check ANIX's fair value in chart for subscribers. The fair value of Anixa Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Anixa Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Anixa Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ANIX is over valued or under valued. Whether Anixa Biosciences Inc is cheap or expensive depends on the assumptions which impact Anixa Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIX.

What is Anixa Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ANIX's PE ratio (Price to Earnings) is -9.62 and Price to Sales (PS) ratio is 492.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIX PE ratio will change depending on the future growth rate expectations of investors.